• Most Popular
  • Most Shared

Intercell says Merck begins S.aureus vaccine trial

Thu Aug 28, 2008 4:31am EDT

Stocks

   

VIENNA, Aug 28 (Reuters) - Austrian biotech firm Intercell (ICEL.VI) said on Thursday its partner Merck & Co (MRK.N) has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.

Stocks

The vaccine candidate is based on a conserved protein antigen discovered by Intercell and licensed to Merck in 2004.

Staphylococcus aureus is the most frequent cause of hospital-acquired infections, Intercell said in a statement.

This is the second trial start following a separate Phase II trial launch in December 2007.

Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales. (Reporting by Karin Strohecker; Editing by Greg Mahlich)

Stocks


More from Reuters

Photo

U.S. probing if al Qaeda linked to airplane incident

WASHINGTON (Reuters) - The United States is investigating whether al Qaeda was involved in a Christmas Day attempt to blow up a passenger jet, but there is no early evidence the Nigerian suspect in the case was part of a larger plot, a senior U.S. official said on Sunday. | Video

» More Top News
A Delta Airbus 330 airliner sits on a runway at Detroit Metropolitan Airport in Romulus, Michigan in this video grab made December 25, 2009. Credit: REUTERS/WDIV TV/Handout

The battle in mid-air

The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers.  Full Article 

U.S.
A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
Political Risk in 2010:

Don't say we didn't warn you

With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

Global Markets